ALX Oncology Holdings Inc. (ALXO) - Market Cap to Net Income Ratio

Corporate emblem and logo of ALX Oncology Holdings (ALXO)

ALX Oncology Holdings (ALXO) possesses colossal pricing power due to the uniqueness of its erythrocyte-sparing product. The development's safety profile allows the company to capture a significant market share without engaging in price wars. The share price history, featuring the -1.70 metric, completes a picture where growth is constrained only by patent complexities and stringent safety requirements. The business relies on the creation of immune-based drugs to combat tumors.

ALXO ALX Oncology Holdings Inc.: Price to Earnings Ratio in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for ALX Oncology Holdings

Comprehensive company analysis:ALXO ALX Oncology
Manufactured product of ALX Oncology

ALX Oncology Holdings (ALXO) focuses on the aggressive development of its CD47-blocker pipeline, positioning the company as a classic representative of the high-tech biopharmaceutical sector. By analyzing the company's historical P/E chart, an investor assesses the ratio of market capitalization to net income to determine the extent to which the asset's value is inflated relative to its current efficiency. The dynamics of this multiple allow for a correlation between expectations for breakthrough evorpacept releases and the actual fundamental stability of the business.

Competing companies

Market Cap to Earnings ImmunityBio IBRX|P/E Multiple IMCR|Janux Therapeutics (JANX) - Market Cap to Net Income Ratio|Arcus Biosciences Inc - Price to Earnings Ratio|Zymeworks (ZYME) - Market Cap to Earnings|TNGX: Price to Earnings Ratio|Company Value to Net Income IOVA (Iovance Biotherapeutics, Inc.)|IMTX: P/E Multiple|XNCR - Business Payback Period|Price to Earnings Ratio compasstherapeutics.com|Price to Earnings Ratio replimune.com (REPL)|Price to Earnings Ratio Lyell (LYEL)|Price to Earnings Ratio Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Price to Earnings Ratio|P/E Multiple Compugen Ltd. CGEN|IOBT - Price to Earnings Ratio|STRO (sutrobio.com) - Price to Earnings Multiple|MiNK Therapeutics, Inc (INKT) - Price to Earnings Ratio|Market Cap to Earnings Werewolf Therapeutics (HOWL)|Price to Earnings Ratio IMMX|CUE (Cue Biopharma, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio PDSB (PDS Biotechnology)|Market Price to Net Income Ratio SONN|P/E Multiple MAIA (MAIA Biotechnology, Inc.)|Company Value to Net Income LIMN|Lava Tx - P/E Multiple|Market Cap to Earnings NextCure Corporation|Leap Tx (LPTX) - Price to Earnings Ratio|Intensity Therapeutics Inc - Company Value to Net Income|SNSE (Sensei Bio) - P/E Multiple|P/E Multiple Theriva Biologics Inc|Price to Earnings Ratio gritstonebio.com (GRTS)|P/E Multiple Kineta Bio (KA)|NexImmune Inc - Price to Earnings Ratio|turnstonebio.com (TSBX) - Market Cap to Earnings|VCNX: Price to Earnings Ratio|Company Value to Net Income HARP (Harpoon Therapeutics, Inc.)